Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT02283684 Completed - Clinical trials for Benign Prostatic Hyperplasia

GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT

Start date: September 2014
Phase: Phase 4
Study type: Interventional

With a growing body of knowledge on the promising advancements and recent clinical data of the third generations of the Greenlight PVP/XPS, it seems to be a real contender in the world of MIS. Contenders of Greenlight laser technology includes bipolar as well as Holmium laser technology. In this study the investigators planned to test the Greenlight (532-nm) laser PVP using (XPS) 180W system compared to bipolar electro-vaporization, in reduction of LUTS secondary to small to moderate sized BPH in a prospective randomized trial.

NCT ID: NCT02252367 Completed - Clinical trials for Lower Urinary Tract Symptoms

Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

Start date: December 2015
Phase: Phase 4
Study type: Interventional

At present time several preclinical and clinical study have demonstrated the safety and efficacy of PDE5 (phosphodiesterase type 5)-inhibitors for LUTS/BPH (lower urinary tract symptoms/benign prostatic hyperplasia) patients with or without erectile dysfunction. However, the link between clinical outcomes (symptoms scores), functional activity (urodynamic findings) and molecular pathways, in particular regarding inflammatory pattern (molecular analyses), has not been previously investigated. Aim of present study is to assess, for the first time in literature, changes in pressure flow study (PFS) and changes in molecular profile of prostatic tissue (inflammatory and tissue remodeling markers) in men treated for 12 weeks with tadalafil 5 mg compared with placebo and to correlate these data with changes in symptoms scores (IPSS, International Prostatic Symptoms Score) in men with LUTS secondary to BPH refractory to alpha blockers.

NCT ID: NCT02248467 Completed - Obesity Clinical Trials

Study of the Effect of Testosterone Treatment on Metabolic Parameters and Urinary Symptoms in Bariatric Patients

Start date: May 2013
Phase:
Study type: Observational

The primary purpose of the study is to evaluate, in obese and hypogonadal patients eligible for bariatric surgery, the effect of testosterone replacement therapy in improving lower urinary tract symptoms (LUTS) assessed using the IPSS (International Prostate Symptom Score) questionnaire, compared to hypogonadal untreated subjects and eugonadal subjects.

NCT ID: NCT02245555 Completed - Clinical trials for Prostatic Hyperplasia

Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Start date: April 2006
Phase: N/A
Study type: Observational

Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia

NCT ID: NCT02245542 Completed - Clinical trials for Prostatic Hyperplasia

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Start date: April 2005
Phase: N/A
Study type: Observational

Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia

NCT ID: NCT02245529 Completed - Clinical trials for Prostatic Hyperplasia

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Start date: March 2005
Phase: N/A
Study type: Observational

The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings. The aim of a PEM is to monitor the safety profile of Secotex® in a cohort of patients with Benign Prostatic Hyperplasia as used in general practice

NCT ID: NCT02245503 Completed - Clinical trials for Prostatic Hyperplasia

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Start date: May 2003
Phase: N/A
Study type: Observational

The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).

NCT ID: NCT02245490 Completed - Clinical trials for Prostatic Hyperplasia

Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

Start date: January 2003
Phase: Phase 4
Study type: Interventional

Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms

NCT ID: NCT02244346 Completed - Clinical trials for Prostatic Hyperplasia

Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Start date: May 2004
Phase: N/A
Study type: Observational

Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice

NCT ID: NCT02244333 Completed - Clinical trials for Prostatic Hyperplasia

Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

Start date: February 2004
Phase: N/A
Study type: Observational

Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment